TECTONIC THERAPEUTIC, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
TECTONIC THERAPEUTIC, INC. (TECX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $0.79 per share for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-03-14
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $1.29, a 87.93% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $10.69, a 21.86% decline year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $13.68, a 19.89% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2019-03-31 was $11.41, a 63.23% increase year-over-year.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $0.79, a 20.20% decline from fiscal 2022.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $0.99, a 88.62% decline from fiscal 2021.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $8.70, a 29.15% decline from fiscal 2020.
- TECTONIC THERAPEUTIC, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $12.28, a 5.77% increase from fiscal 2019.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.79 10-K · filed 2024-03-14 | |||
| 2023-09-30 | $0.79 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $0.79 10-Q · filed 2023-08-10 | |||
| 2022-12-31 | $0.99 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $1.23 10-Q · filed 2023-11-09 | |||
| 2022-06-30 | $1.23 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $1.29 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $8.70 10-K · filed 2023-03-23 | |||
| 2021-09-30 | $9.12 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $9.31 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $10.69 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $12.28 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $12.98 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | $13.16 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | $13.68 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $11.61 10-K · filed 2021-03-18 | |||
| 2019-09-30 | $11.77 10-Q · filed 2020-11-05 | |||
| 2019-06-30 | $11.37 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | $11.41 10-Q · filed 2020-05-07 | |||
| 2018-12-31 | $10.91 10-K · filed 2020-03-16 | |||
| 2018-09-30 | $9.05 10-Q · filed 2019-11-07 | |||
| 2018-06-30 | $7.63 10-Q · filed 2019-08-08 | |||
| 2018-03-31 | $6.99 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | $1.50 10-K · filed 2019-03-25 | |||
| 2017-09-30 | $1.14 10-Q · filed 2018-11-13 | |||
| 2017-06-30 | $0.66 10-Q · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |